Your Article Summary
See Latest ArticlesAbbott Receives CE Mark for Company's Next-Generation XIENCE PRIME Drug Eluting Stent, Advancing Leadership Position
Abbott, 06/24/09
Abbott announced that it has received CE Mark for its next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Non-adherence to statin therapy: a major challenge for preventive cardiology
Expert Opinion in Pharmacotherapy, 12/08/09
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management
Pharmacoepidemiology and Drug Safety, 12/08/09
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09